UBS Group’s Xenetic Biosciences XBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.35K | Buy |
+1,013
| New | +$3.19K | ﹤0.01% | 10020 |
|
|
2025
Q4 | – | Sell |
-497
| Closed | -$1.56K | – | 11244 |
|
|
2025
Q3 | $1.56K | Buy |
+497
| New | +$1.62K | ﹤0.01% | 9320 |
|
|
2025
Q2 | – | Sell |
-2,531
| Closed | -$6.6K | – | 10895 |
|
|
2025
Q1 | $6.6K | Buy |
2,531
+875
| +53% | +$3.42K | ﹤0.01% | 8888 |
|
|
2024
Q4 | $6.61K | Buy |
+1,656
| New | +$6.68K | ﹤0.01% | 8544 |
|
|
2024
Q3 | – | Sell |
-182
| Closed | -$741 | – | 10124 |
|
|
2024
Q2 | $741 | Sell |
182
-2,893
| -94% | -$11.7K | ﹤0.01% | 8786 |
|
|
2024
Q1 | $11.6K | Buy |
3,075
+2,770
| +908% | +$10.6K | ﹤0.01% | 7174 |
|
|
2023
Q4 | $1.05K | Buy |
+305
| New | +$1.07K | ﹤0.01% | 8419 |
|
|
2022
Q4 | – | Sell |
-786
| Closed | -$4K | – | 11198 |
|
|
2022
Q3 | $4K | Buy |
786
+694
| +754% | +$5.48K | ﹤0.01% | 9406 |
|
|
2022
Q2 | $1K | Buy |
+92
| New | +$744 | ﹤0.01% | 9980 |
|
|
2022
Q1 | – | Sell |
-606
| Closed | -$8K | – | 10974 |
|
|
2021
Q4 | $8K | Buy |
606
+341
| +129% | +$5.44K | ﹤0.01% | 9064 |
|
|
2021
Q3 | $5K | Sell |
265
-256
| -49% | -$6.98K | ﹤0.01% | 8565 |
|
|
2021
Q2 | $11K | Buy |
521
+424
| +437% | +$8.55K | ﹤0.01% | 7985 |
|
|
2021
Q1 | $2K | Buy |
+97
| New | +$2.55K | ﹤0.01% | 8652 |
|
|
2020
Q4 | – | Sell |
-940
| Closed | -$9K | – | 8816 |
|
|
2020
Q3 | $9K | Buy |
+940
| New | +$10.1K | ﹤0.01% | 6956 |
|
|
2020
Q1 | – | Sell |
-976
| Closed | -$14K | – | 8478 |
|
|
2019
Q4 | $14K | Buy |
976
+699
| +252% | +$8.88K | ﹤0.01% | 7099 |
|
|
2019
Q3 | $3K | Buy |
277
+92
| +50% | +$3.29K | ﹤0.01% | 7666 |
|
|
2019
Q2 | $21K | Buy |
185
+173
| +1,442% | +$22.9K | ﹤0.01% | 6582 |
|
|
2019
Q1 | $3K | Sell |
12
-5
| -29% | -$1.22K | ﹤0.01% | 7351 |
|
|
2018
Q4 | $3K | Buy |
+17
| New | +$5.15K | ﹤0.01% | 7740 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 8310 |
|
|
2018
Q2 | – | Sell |
-22
| Closed | -$5.62K | – | 8300 |
|
|
2018
Q1 | $6K | Sell |
22
-9
| -29% | -$2.26K | ﹤0.01% | 7166 |
|
|
2017
Q4 | $7K | Buy |
31
+15
| +94% | +$4.25K | ﹤0.01% | 7245 |
|
|
2017
Q3 | $4K | Buy |
16
+12
| +300% | +$3.88K | ﹤0.01% | 7325 |
|
|
2017
Q2 | $1K | Buy |
+4
| New | +$1.71K | ﹤0.01% | 7525 |
|
|
2017
Q1 | – | Sell |
-2
| Closed | -$1K | – | 8026 |
|
|
2016
Q4 | $1K | Buy |
+2
| New | +$862 | ﹤0.01% | 7650 |
|
Other funds holding XBIO
UBS Group's XBIO Position: Q3 2026 in Review
UBS Group opened a new position in Xenetic Biosciences (XBIO) in Q3 2026: 1,013 shares worth $2.35K. The stake represents ﹤0.01% of the portfolio and ranks #10020 among its holdings. This is a return to the name: UBS Group previously reported a position in XBIO as recently as Q3 2025.
UBS Group first reported a position in XBIO in Q4 2016 and has held it in 24 quarters since. The position peaked at $21K in Q2 2019. 12 funds tracked by Wall St. Rank hold XBIO as of Q3 2026.
- UBS Group held 1,013 shares of Xenetic Biosciences worth $2.35K as of Q3 2026.
- Xenetic Biosciences was a new UBS Group position in Q3 2026.
- Xenetic Biosciences made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10020 holding.
- UBS Group first reported a position in Xenetic Biosciences in Q4 2016 and has held it in 24 quarters since.
- UBS Group's Xenetic Biosciences position peaked at $21K in Q2 2019.
- 12 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.